Prospects for HIV-1 therapeutic immunisation and vaccination: The potential contribution of peptide immunogens

Expert Opinion on Biological Therapy

Volumn 8, Issue 6, 2008, Pages 745-757

  Sommerfelt, Maja A ^a   Sørensen, Birger ^a  

^a BIONOR   (Norway)

Author keywords

HIV 1; Immunotherapy; Peptide; Preventative vaccine; Therapeutic immunisation; Therapeutic vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EFAVIRENZ; ENFUVIRTIDE; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOPEPTIDE; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; PLACEBO; SYNTHETIC PEPTIDE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION CONTROL; INFECTION PREVENTION; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; T LYMPHOCYTE; TERATOGENICITY; THERAPY DELAY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; EPITOPES; FORECASTING; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; T-LYMPHOCYTE SUBSETS; VACCINATION; VACCINES, SUBUNIT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 45549086967     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.6.745     Document Type: Review

References (105)

1. El-Sadr VM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med 2006;355:2283-96 •• This is the largest treatment-interruption study carried out to date.
2. Cohen J. Promising AIDS vaccine's failure leave field reeling. Science 2007;318:28-9
3. UNAIDS Report 2007. Available from: http://www.unaids.org/en/ KnowledgeCentre/HIVData/EpiUpdate/ EpiUpdArchive/2007default.asp [Last accessed 2 April 2008]
4. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-20
5. Bisson G, Gross R, Miller V, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003;17:2407-17
6. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62
7. Wand H, Calmy, A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-53
8. Haas DW. Pharmacogenomics and HIV therapeutics. J Infect Dis 2005;191:1397-400
9. Powderly WG. The three ages of antiretroviral therapy - its evolution and the emergence of long-term safety concerns. Eur Infect Dis 2007;1:19-25
10. Kavlick MF, Mitsuya H. Emergence of drug resistant human immunodeficiency virus (HIV-1) variants and their impact on antiretroviral thetapy of HIV-1 infection. In: E De Clerq, editor, Antiretroviral therapy. ASM Press: Washington DC; 2001
11. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-52
12. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Def Syndr 2007;43:27-34
13. Youle M, Wainberg MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 2003;17:937-8. • This paper marks the first time, to our knowledge, that the concept of pre-exposure prophylaxis was raised.
14. Youle M, Wainberg MA. Pre-exposure prophylaxis (PREP) as an HIV prevention strategy. JIAPAC 2003;2:102-5
15. Grant RM, Buchbinder S, Cates W, et al. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005;309;2170-1
16. Abbas U, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource limited settings. PLoS One 2007;2:e875. Published online September 19, 2007, doi:10.1371/journal.pone. 0000875
17. CDC Trials of Pre-Exposure Prophylaxis for HIV Prevention 2007. Available from: http://www.cdc.gov/hiv/resources/factsheets/ prep.htm [Last accessed 2 April 2008]
18. Centres for Disease Control. Update: Provisional public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. JAMA 1996;276:90-2
19. Braitstein P, Chan K, Beardsell A, et al. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquir Imm Def Syndr 2002;29:547-8
20. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004;10:806-10 •• An excellent overview discussing the quality of the immune responses to HIV.
21. Zhu T, Corey L, Hwangbo Y, et al. Persistence of exttaordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003;77:6108-16
22. Kaul R, Rowland-Jones S.L, Kimani J. Late seroconversion in HIV resistant Nairobi prostitutes despite pre-existing HIV-specific CD8 responses. J Clin Invest 2001;107:341-9
23. Buchbinder SP, Katz MH, Hessol NA, et al. Long-term HIV infection without immunological progression. AIDS 1994;8:1123-8
24. Lefrere J-J, Morand-Joubert L, Mariotti M, et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997;90:1133-40
25. Walker B. Elite control of HIV infection: Implications for vaccines and treatments. Top. HIV Med 2007;15:134-6
26. Sáez-Cirión A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007;104:6776-81
27. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cells response to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53 •• An interesting overview showing how Gag responses appear to be associated with a low viral setpoint whereas Env responses are associated with elevated viraemia.
28. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987;327:473-6 * The first time, to our knowledge that the concept of therapeutic immunisation was raised for HIV.
29. Levy JA. HIV and the pathogensis of AIDS. 3rd edition. Washington: ASM Press; 2007
30. Gazzard B. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2005. HIV Med 2005;6(Suppl. 2):1-61
31. Bartlett JC, Lane HC, et al. Guidelines on the use of antiretroviral agents in HIV-1-infected adults and adolescents May 4 2006. Available from: http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL05042006050.pdf [Last accessed 3 April 2008]
32. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 Recommendations of the international AIDS society - USA panel. JAMA 2004;292:251-65 • This paper represents the first move towards CD4+ T-cell counts as an important marker of immunological fitness.
33. Lederman MM, Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 2001;2:S11-5
34. Douek DC, Brenchly JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T-cells. Nature 2002;417:95-8
35. Bryan CS. Hit Early Hit Hard: new strategies for HIV. JSC Med Assoc 1996;92:361-3
36. Chopra KF, Tyring SK.Current antiretroviral therapy in the treatment of HIV infection. Semin Cutan Med Surg 1997;16:224-34
37. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viraemia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005;192:607-17
38. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral thetapy commenced early during the course of human immunodeficiency virus infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-43
39. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 2001;286:2981-7 •• An interesting review describing differential effects of viral rebound following treatment interruption in chronic and acute HIV infection.
40. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006;368:451-8 •• This article shows that during the 10 years of ART, many patients initiated ART at levels well below 200 cells/μl.
41. Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy be started? BMJ 2007;334:76-8 •• This paper provides one review of the SMART study and suggests amended guidelines for initiation of ART at higher CD4+ T-cell levels.
42. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008 January 29; 1-128. Available from: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf [Last accessed 3 April 2008]
43. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006;367:1981-9
44. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4 guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet 2006;368:459-65
45. Maggiolo F, Ripamonti D, Gregis G. Effects of prolonged discontinuation of successful antiretroviral therapy on CD4 T-cells: a controlled, prospective trial. AIDS 2004;18:439-46
46. Mussini C, Bedini A, Borghi V, et al. CD4 cell-monitored treatment interruption in patients with CD4 cell count >500 x 106 cells/l. AIDS 2005;19:287-94
47. Giuntini R, Martinelli C, Ambu S, et al. Prolonged treatment interruption in chronic HIV infection: a new strategy? AIDS 2005;19:209-15
48. Boschi A, Tinelli C, Ortolani P, et al. CD4+ cell count guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS 2004;18:2381-9
49. Ananworanich J, Hirschel B. Interrupting highly active antiretroviral therapy in patients with HIV. Expert Rev Anti Infect Ther 2005;3:51-60
50. Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007;21:1673-82 •• This paper suggests different scenarios for safely stopping ART.
51. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmocogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42:401-7
52. Wit FW, Blackenberg DH, Brinkman K, et al. Safety of long-term interruption of successful antiretroviral therapy: The ATHENA cohort study. AIDS 2005;19:345-8
53. Hasson H, Mantelli B, Biswas P, et al. Favourable outcome of Ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1. J Med Virol 2007;79:1640-9
54. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Eng J Med 2001;344:472-80
55. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of latent reservoir for HIV-1 in resting CD4+ T-cells. Nat Med 2003;9:727-8
56. Forster SM, Osborne LM, Cheinsong-Popov R, et al. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. AIDS 1987;1:235-40
57. Weber J, Clapham P, Weiss RA, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet 1987;1:119-22
58. Pedersen C, Nielsen CM, Vestergaard BF, et al. Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. BMJ 1987;295:567-9
59. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50
60. Zuniga R, Lucchetti A, Galvon E et al. Relative dominance of Gag p24-specific cytotoxic T-lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122-5
61. Graham BS, Mascola JR. Lessons from failure: preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005;191:647-9
62. Gilbert PB, Peterson, ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-77
63. Esparza J, Russell ND. The HIV vaccine pipeline In: Koff WC, Kahn P, Gust ID, editors. AIDS vaccine development: challenges and opportunities. Caister Academic Press; 2007. p. 77-86
64. IAVI Database of AIDS Vaccines In Human Trials. Available from: http://www.iavireport.org/trialsdb/ [Last accessed 3 April 2008]
65. Yuki Y, Nochi T, Kiyono H. Progress towards an AIDS mucosal vaccine: an overview. Tuberculosis 2007;87:S35-44
66. Johnston M, Fauci A. An HIV vaccine - evolving concepts. N Engl J Med 2007;356:2073-81 •• This article suggests for the first time, to our knowledge, that preventative T-cell based vaccines need not completely prevent infection, but may allow patients improved virus control should infection occur.
67. Cohen J. Did Merck's failed HIV vaccine cause harm? Science 2007;318: 1048-9
68. Data from STEP study presented at open scientific session confirm Merck's investigational HIV vaccine was not effective. Available from: http://www.avac. org/pdf/STEP_data_release.7Nov.pdf
69. Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis 2008;8(2):82-3
70. Hanke T, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focussing on T-cell induction. J Gen Virol 2007;88:1-12
71. Wee EG, Patel S, McMichael AJ, Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 2002;83:75-85
72. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-71
73. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296;2354-60
74. Weaver EA, Lu Z, Camacho ZT, et al. Cross sub-type T-cell immune responses induced by a human immunodeificiency virus type 1 group M consensus Env immunogen. J Virol 2006;80;6745-56
75. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV variants. Nat Med 2007;13:100-6
76. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006;80:3617-23
77. Kran AMB, Jonassen TØ, Lovgården G, et al. 2007. Low frequency of escape mutations after 15 months viraemia following efficient therapeutic immunization using conserved HIV p24-like peptides. Keystone Symposium HIV Vaccines: From Basic Research to Clinical Trials. March 2007 25-30, Whistler ResortWhistler, British Columbia
78. Geels MJ, Dubey SA, Anderson K, et al. Broad cross clade T-cell response to Gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of the HLA anchor residue conservation. J Virol 2005;79:11247-58
79. Okazaki T, Terabe M, Catazaro AT, et al. Possible therapeutic strategy against human immunodeficiency virus escape from reverser transcriptase inhibitors studied in HLA-A2 transgenic mice. J Virol 2006;80:10645-51
80. De Groot AS, Jesdale B, Martin W, et al. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 2003;21:4486-504
81. Vider-Shalit T, Raffaeli S, Louzoum Y. Virus-epitope vaccine design: Informatic matching the HLA-I polymorphism to the virus genome. Mol immunol 2007;44:1253-61
82. Jiang S, Song R, Popov S, et al. Overlapping synthetic peptides as vaccines. Vaccine 2006;24:6356-65
83. Le Gall S, Stamegna P, Walker BD. Portable flanking sequences modulate CTL epitope processing. J Clin Invest 2007;117:3563-75
84. Migueles SA, Sabbaghian MS, Schupert WL, et al. HLA-B5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long-term nonprogressors. Proc Natl Acad Sci USA 2000;97:2709-14
85. Itescu S, Mathur-Wagh U, Skovron ML, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immun Def Syndr 1992;5:37-45
86. Yu XG, Lichterfield M, Chetty S, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with two amino acid differences between HLA class subtypes. J Virol 2007;81:1619-31
87. Kran A-M B, Sorensen B, Nyhus J, et al. HLA and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004;18:1875-83
88. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1 infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2003;103:966-72
89. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viraemia following therapeutic immunization in chronically HIV-1 infected individuals. AIDS 2006; 404-413
90. Levy Gahery-Segard H, Durier C et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin 2 in chronically HIV-1 infected patients. AIDS 2005;19:279-286
91. Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: Impact of a therapeutic vaccination strategy combined eith interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized study. AIDS Res Hum Retroviruses 2007;23:1105-13
92. Kilby JM, Bucy RP, Mildvan D, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006;194:1672-6
93. DeVito C, Zuber B, Schröder U, et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralising humoral mucosal and systemic immunity. J Immunol 2004;173:7078-89
94. Lori F, Calarota SA, Lisziewics J. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem 2007;14:1911-9
95. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-65 •• This paper showed for the first time, to our knowledge, the power of ex vivo dendritic cell immunisation to control HIV infection. Patients were immunised with their own virus that had been inactivated.
96. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-5
97. Liu K, Iyoda T, Satemus M, et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002;196:1091-7
98. Belyakov IM, Hammond S, Ahlers JD, et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004;113:998-1007
99. Gahery H, Daniel N, Charmeteau B, et al. New CD4 and CD8 T-cell responses induced in chronically HIV type 1 infected patients after immunisations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses 2006;22:684-94
100. Frey S, Pieperl L, Baden L, et al. Safety of ANRS LIPO-5 alone, sanofi-pasteur ALVAC-HIV (vCP1452) alone and ALVAC HIV prime/LIPO5 boost in healthy uninfected adult participants. AIDS Vaccine Conference; September 6-9; 2005, Montreal, Canada
101. Durier C, Launay O, Meiffredy V, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006;20:1039-49
102. Launay O, Durier C, Desaint C, et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV uninfected volunteers in the ANRS VAC16 trial. PLoS One 2007;8:e725. Published online August 22, 2007, doi:10.1371/journal.pone.0000725
103. Kran AM, Sommerfelt MA, Sørensen B, et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005;23:4011-5
104. Kran AMB, Sørensen B, Sommerfeit MA. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006;20:627-9
105. Donaghy H, Stebbing J, Patterson S. Antigen presentation and the role of dendritic cells in HIV Curr opin Infect Dis 2004;17:1-6 •• An interesting review discussing the potential effect on disease course of HIV infection of dendritic cells.